News
sleep apnea
Wet AMD risk linked to sleep apnea
Researchers at the Center for Eye Research in Australia have discovered a possible link between moderate-to-severe obstructive sleep apnea (OSA) and wet age-related macular degeneration.
AMD
Study finds that AREDS 2 supplementation helps slow progression of late-stage macular degeneration
While researchers have known that AREDS 2 supplements help slow the progression of AMD from the intermediate stage to the late stage, they wanted to establish whether supplementation could impact t...
age-related macular degeneration
Researchers working on possible alternative treatment for wet AMD
Researchers have recently discovered that the enzyme, telomerase, plays a role in abnormal blood vessel formation in lab mice and this discovery may lead to new therapies in treating the wet form ...
EyePoint
New AMD drug completes Phase 2 trial
EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.
intravitreal injection
New eye drops may be potential new treatment for wet AMD
The current available therapies available to treat wet AMD involve intravitreal injections delivered every month to the back of the eye.
diabetic macular edema
Regeneron receives FDA approval for EYLEA HD
The Food and Drug Administraton (FDA) gave approval after two active-controlled, double-masked pivotal trials, which compared EYLEA HD to EYLEA over a 48 week period.
AMD
FDA approves Izervay for treatment of geographic atrophy
The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
anti-VEGF
New anti-VEGF therapy shows promise in Phase 1 Clinical trial
The new drug is manufactured by 4D Molecular Therapeutics and is a dual-transgene intravitreal gene therapy.
AMD
AI algorithm may be a helpful tool for determining progression of AMD
Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.